Kaposi’s sarcoma: Good outcome with doxorubicin bleomycin and vincristine sulphate ABV chemotherapy and highly active antiretroviral therapy
| Autor: | P Hesseling, P Wharin, M Kruger, F Kouya, E Katayi, R Bardin, D Palmer, M Glenn |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: | |
| Zdroj: | South African Medical Journal, Vol 107, Iss 11, Pp 952-953 (2017) |
| Druh dokumentu: | article |
| ISSN: | 2078-5135 0256-9574 |
| DOI: | 10.7196/SAMJ.2017.v107i11.12559 |
| Popis: | There is little published information on effective treatment of Kaposi’s sarcoma (KS) in children in low-income countries. We prospectively treated 12 patients with an institutional review board-approved protocol consisting of four monthly courses of doxorubicin (Adriamycin), bleomycin and vincristine sulphate (ABV), with highly active antiretroviral therapy (HAART) plus co-trimoxazole prophylaxis for those who were HIV-positive, with additional vincristine if remission was not achieved after 4 months. Maintenance HAART plus co-trimoxazole was given to all HIV-positive patients. A fine-needle aspirate and CD4+ count were done if possible, and staging was performed according to Mitsuyasu. Eight of ten HIV-positive patients with stage III - IVB disease, and both HIV-negative patients with stage I disease, were in remission after 473 - 1 490 (mean 939) days. One patient died after absconding during treatment, and one died from neutropenia-related pulmonary infection. ABV with or without HAART is an effective treatment option for children with KS. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|